Harvard Bioscience Reports Third-Quarter 2026 Results, Reaffirms Guidance
Harvard Bioscience reported third-quarter 2026 revenue of $22.2 million, versus $20.6 million a year earlier, and gross margin of 55.4%. Nine-month revenue was $65.7 million, compared with $62.8 million. The company reaffirmed full-year revenue growth guidance of 3% to 5% and adjusted gross margin guidance of 57% to 59%, and updated its adjusted EBITDA target.
Harvard Bioscience reported third-quarter 2026 revenue of $22.2 million, up from $20.6 million in the same period of 2025. The company achieved a gross profit of $12.3 million with a gross margin of 55.4%. For the first nine months of 2026, revenue reached $65.7 million compared to $62.8 million in the prior year. Management highlighted strong double-digit revenue growth to contract research organizations (CROs) and other customers.
The company reaffirmed its full-year 2026 revenue growth guidance of 3% to 5% and adjusted gross margin guidance of 57% to 59%, while updating its adjusted EBITDA target to reflect higher sales of certain lower-margin products and increased revenue contributions from China and distribution channels.